The Long-Term Use of Pipecuronium in Cardiac and Esophageal Surgery Patients

  • Tadashi Aoki
Conference paper


We studied 24 patients undergoing cardiac surgery or esophagectomy, and necessitating postoperative mechanical ventilation. The initial and maintenance doses of pipecuronium (0.08 mg/kg which is approximately 2 × ED95, and 0.04 mg/kg, respectively) were given during the surgery, and the continuous intravenous infusion of pipecuronium was given in the ICU after surgery. The neuromuscular blockades (NMBs) produced by the relaxant were evaluated with an evoked compound electromyogram. The plasma concentrations of pipecuronium were determined 5 min after the administration of pipecuronium, at 10 % recovery from the complete NMB during surgery and one time a day during the continuous intravenous infusion of the drug in the ICU. The clinical durations of the maintenance dose of pipecuronium in the hypothermic state (core temperature 25.8±0.3° C) during cardiopulmonary bypass (CPB) and in the normothermic states, before and after CPB (core temperature 36.0±0.2°C and 35.7±0.3°C) were 295±18, 107±13 and 143±18 minutes, respectively. The repeated administration of the maintenance dose did not produce prolongation of the clinical duration in the normothermic state of esophagectomy patients. The required infusion rates of pipecuronium were 0.035±0.004 mg/kg/h (0.02–0.06 mg/kg/h) in the ICU. The plasma concentrations of pipecuronium 5 min after the administration of it in cardiac surgery and esophagectomy patients were 508.0±71.3 ng/ml, 524.0±45.0 ng/ml in the initial dose, and 418.3±31.3 ng/ml, 413.7±31.5 ng/ml in the maintenance dose, respectively. The plasma concentrations of pipecuronium for 90% block in hypothermic state of cardiac surgery patients and in normothermic state of esophagectomy patients were 38.8±4.9 ng/ml (23.3–59.8 ng/ml) and 117.0±10.3 ng/ml (50.2–192.1 ng/ml), respectively.


Maintenance Dose Neuromuscular Blockade Continuous Intravenous Infusion Cardiac Surgery Patient Skin Surface Temperature 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Agoston S. The use and misuse of neuromuscular blocking agents in the intensive care unit. In Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 109–16.Google Scholar
  2. 2.
    Miller RD. Pharmacokinetics of neuromuscular blocking drugs in intensive care patients. In Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 117–125.Google Scholar
  3. 3.
    Coursin DB, Klasek G, Goelzer S. Increased requirements for continuously infused vecuronium in critically ill patients. Anesth Analg 1989; 69: 518–521.PubMedCrossRefGoogle Scholar
  4. 4.
    Griffin D, Fairman N, Coursin D, Rawsthorne L, Grossman JE. Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants. Chest 1992; 102: 510–514.PubMedCrossRefGoogle Scholar
  5. 5.
    Klessig HT, Geiger RJ, Murray MJ, Coursin DB. A national survey on the practice patterns of anesthesiologists in the use of muscle relaxants. Crit Care Med 1992; 20: 1441–1445.CrossRefGoogle Scholar
  6. 6.
    Hansen-Flaschen JH, Brazinsky S, Basile C, Lanken PN. Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. JAMA 1992; 266: 2870–2875.CrossRefGoogle Scholar
  7. 7.
    Khuenl-Brady KS, Reitstatter B, Schlager A, Schreithofer D, Luger T, Seyr M, Mutz N, Agoston S. Long-term administration of pancuronium and pipecuronium in the intensive care unit. Anesth Analg 1994; 78: 1082–1086.PubMedCrossRefGoogle Scholar
  8. 8.
    Tsuchihashi H, Tatsuno M, Nishikawa M. The analysis of quaternay ammonium compounds by pyrolysis gas chromatography/mass spectrometry and thin-layer chromatography. EISEI KAGAKU 1990; 36: 28–35.CrossRefGoogle Scholar
  9. 9.
    Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. 1987; 67: 1149–1153.Google Scholar
  10. 10.
    Foldes FF, Kuze S, Vizi ES, Deery A. The influence of temperature on neuromuscular performance. J Neural Transmission 1978; 43: 27–45.CrossRefGoogle Scholar
  11. 11.
    Smith NT, Corbacio AN. Drug interaction in anesthesia. 1986; 2nd Edition: 363–390, Lea & Febiger, Philadelphia.Google Scholar
  12. 12.
    Miller RD, Savarese JJ. Pharmacology of muscle relaxants, their antagonists, and monitoring of neuromuscular function. Anesthesia 1981; Vol. 1. Edited by Miller RD: 487–538, Churchill Livingstone, New York.Google Scholar
  13. 13.
    Agoston S, Wierda Swen J. The clinical pharmacology of pipecuronium bromide. In Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica, 1990; 137–147.Google Scholar
  14. 14.
    Tassonyi E, Szabo G, Vimlati L. The use of pipecuronium — Arduanr — in anaesthesiology. In: Kharkevich DA, ed. Handbook of experimental pharmacology. 1986; vol. 79. 599–616.Google Scholar
  15. 15.
    Wierda JMKH, Richardson OM, Agoston S. Dose response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol/fentanyl. Anesth Analg 1989; 69: 208–213.Google Scholar
  16. 16.
    Segredo V, Matthay MA, Sharma ML, Gruenke LD, Caldwell JE, Miller RD. Prolonged neuromuscular blockade after long-term administration of vecuronium in two critically ill patients. Anesthesiology 1990; 72: 566–570.PubMedCrossRefGoogle Scholar
  17. 17.
    Cronnelly R, Fisher DM, Miller RD, Gencarelli P, Nguyen-Gruenke L, Castagnoli Jr N. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC45) and pancuronium in anesthetized man. Anesthesiology 1983; 58: 405–408.PubMedCrossRefGoogle Scholar
  18. 18.
    Segredo V, Matthay MA, Caldwell JE, Sharma ML, Grunke LD, Miller RD. Pharmacodynamics of vecuronium after long-term administration. Anesth Analg 1990; 70: S361.CrossRefGoogle Scholar

Copyright information

© Springer Japan 1995

Authors and Affiliations

  • Tadashi Aoki
    • 1
  1. 1.Department of AnesthesiologySt. Marianna University School of MedicineMiyamae-ku, Kawasaki, Kanagawa, 216Japan

Personalised recommendations